expression of IL-6R by leukemic cells from several patients by primary leukemic cells from three of six patients with with t(4;11)+ ALL co-expressing myeloid antigens. To our t(4;11)+ ALL. Scatchard analysis revealed from 960 to 2100 knowledge, this study represents the first detailed report of IL- 
Bone marrow cells were obtained from six patients with Introduction t(4;11)+ ALL in relapse following informed parental consent. Diagnosis was based on the French-American-British (FAB) The t(4;11)(q21;q23) translocation is one of the most common cooperative group classification and cytogenetic finding of chromosomal translocations in pediatric ALL, present in 2-t(4;11). Cells were typed for the following antigens: B cell 3% of newly diagnosed cases.
1 Like certain other nonrandom (CD10, CD19, CD9), myeloid (CD13, CD15, CD33), T cell translocations commonly identified in pediatric ALL, the (CD2, CD5) and T cell/myeloid (CD7). Immunophenotypic t(4;11) abnormality is significant because of its association characteristics of these specimens are given in Table 1 . Leuwith poor prognosis. [2] [3] [4] This translocation has also been assokemic cells were separated by centrifugation over Ficollciated with co-expression of myeloid markers (My+ ALL), age Hypaque; the percentage of leukemic blasts in the post-Ficoll Ͻ1 year at diagnosis, hyperleukocytosis, and CNS involvemononuclear fraction was Ͼ95% by morphologic and ment. The presence of monocytic features in combination immunologic criteria. Cells were morphologically either L1 or with a B cell precursor phenotype suggests that t(4;11)+ ALL L2 (FAB) and negative for myeloperoxidase, Sudan black B, originates from a bipotent stem cell able to differentiate along and both specific and nonspecific esterases. Additionally, both lymphoid and myeloid pathways. Ficoll-Hypaque mononuclear cells from patient UPN 3 in Previous studies have demonstrated the presence of recepremission and from a pediatric solid tumor patient without tors for a number of growth factors on pediatric ALL cells. [6] [7] [8] [9] bone marrow involvement (ie normal bone marrow) were In particular, several studies have detected expression of the analyzed for IL-6R expression. IL-6 receptor (IL-6R) mRNA by leukemic cells from adult patients with acute myeloid leukemia (AML) and acute mixed lineage leukemia (AMLL) expressing both myeloid and lymphoid antigens. [10] [11] [12] During our studies of the in vitro growth label was quantitated by cutting off the tips of the tubes, which contain the cell pellets, and counting in a gamma counter. Free ligand was measured by counting an aliquot of the bindTo investigate the effect of IL6-PE 4E on the growth of myeloid progenitor cells, a methylcellulose assay was performed as ing medium remaining on top of the oil layer after centrifugation. Representation of the data in a Scatchard plot gives the previously described. 21 Ficoll-separated bone marrow mononuclear cells (10 6 cells/ml) were incubated with or without number of receptors/cell (x-axis intercept) and dissociation constant (K d ), equal to the negative-reciprocal slope of the different concentrations of IL6-PE 4E for 24 h, washed twice and cultured in methylcellulose at 10 5 cells/ml. For culture of plot.
granulocyte-macrophage progenitor cells (CFU-GM), the cytokines rhuGM-CSF (100 ng/ml; Immunex) and rhuIL3 (100 U/ml; Genetics Institute, Cambridge, MA, USA) were Proliferation assay added. For culture of early erythroid progenitor cells (burstforming-unit-erythroid, BFU-E), rHuEpo (2 U/ml, Amgen, Leukemic cells (10 5 cells/well) were cultured in RPMI plus 1% serum substitute (ITS, Collaborative Research, Cambridge, Thousand Oaks, CA, USA) and rhuIL-3 (100 U/ml) were added. Cultures were incubated in 7% CO 2 -in-air and scored MA, USA) in 96-well microtiter plates (0.2 ml/well). IL-6 (10 ng/well, equal to 50 ng/ml; Immunex, Seattle, WA, USA) at day 10 for CFU-GM and day 12 for BFU-E (ie distinct aggregates of multiple erythroid colonies), using previously was added and cells incubated for 44 h at 37°C in 7% CO 2 . Twenty-five lambda 3 H-thymidine (DuPont NEN, Boston, MA, described criteria.
22,23
USA; Specific Act. = 20 Ci/mM) was then added to each well (0.5 Ci/well), and cells were incubated another 4 h before harvesting with an automatic harvester. Thymidine uptake was
Leukemic engraftment assay for sensitivity to IL6-PE 4E measured by scintillation counting of triplicate cultures and compared to control cultures with media alone.
To investigate the ability of in vitro treatment with IL6-PE 4E to inhibit tumorigenic growth in SCID mice, bone marrow blasts (10 7 cells/ml) from patients UPN 3 and 4 (Table 1) were incubated with 10 3 ng/ml recombinant toxin for 24 h. Cells were
In vitro cytotoxicity assay for sensitivity to IL6-PE 4E incubated in a total volume of 3 ml with gentle mixing and then washed once. Cell viability by trypan-blue dye exclusion The sensitivity of primary ALL cells to IL6-PE 4E was determined by XTT assay, which has previously been used to measure the was Ͼ50% after 24 h incubation (54 and 62% for UPN 3 and 4, respectively). SCID (C.B-17 scid/scid) mice were injected response of leukemic cells to chemotherapeutic agents in short-term cultures. 20 Cleavage of XTT (a tetrazolium salt) by i.v. with 5 × 10 6 viable IL6-PE
4E
-treated cells (n = 4 mice) or with an equal number of control-treated cells (incubated mitochondrial-associated dehydrogenase enzymes in metabolically active cells yields a colored formazan product that either with IL6-PE 4EAsp553 or with PE40). An additional control consisted of cells incubated with IL6-PE 4E in the presence of some 8, and a third patient (UPN 4) had an isochromosome 7q. Also, UPN 4 had an 11(q23) region deletion affecting the 100-fold excess IL6. Mice were sacrificed after developing signs of disease (ruffled fur, lethargy, abdominal mass). To untranslocated chromosome 11. Immunophenotypes for all patients studied are shown in Table 1 . detect occult disease in surviving mice, we performed PCR analysis to detect a DNA sequence in exon-1 of the human ␤-globin gene. 24 Two 20-mer primers specific for a 110-bp exon-1 fragment were synthesized at the Emory University Microchemical facility based on previously described Quantitation of IL-6R on primary and cultured sequences (PC03 and PC04; Ref. 24) . Sixty cycles of PCR leukemic cells amplification were performed using 1g genomic DNA (obtained from bone marrow, liver and spleen) and a program of 95°C for 1 min, 55°C for 1 min, and 72°C for 1.5 min;
Specific equilibrium binding of 125 I-IL6 to patients' cryopreserved primary leukemic cells was evaluated in a standard additionally, the 72°C elongation step was extended for 2 s after each cycle and for 10 min after 60 cycles. Amplified ligand-binding assay in the presence and absence of a 200-fold excess of unlabeled IL6. Binding was specific and satu-DNA was detected by electrophoresis on 3% agarose gels. Negative controls included genomic DNA from an uninocurable using a 2 h incubation at 4°C, permitting calculation of receptor number and affinity by Scatchard analysis (Figure 1 ). lated SCID mouse as well as PCR reaction buffer without DNA. Positive controls consisted of DNA from inoculated, Binding data yielded straight linear-regression lines, indicating the existence of a single class of high-affinity receptors. The untreated mice following development of symptoms.
range of calculated receptor densities was 960 to 2100, and corresponding receptor affinities (measured as the dissociation constant K d ) were 0.34 nM to 0.50 nM (Table 1 and Figure 1 ).
Results
In contrast, bone marrow mononuclear cells obtained from UPN 3 during remission and from a normal pediatric bone
Characterization of primary t(4;11)+ ALL cells marrow (ie untreated solid tumor patient without bone marrow involvement) failed to specifically bind 125 I-IL6 in the Primary relapse cells from all patients had immunophenotypes typical of t(4;11)+ ALL:
above assay, indicating receptor densities below the limit of detection (Ͻ20/cell). Leukemic cells from patients UPN 3 and Additionally, leukemic cells from IL-6R+ cases were CD33
+ . None of the cells expressed T cell antigens CD2 and 5, 4 were also positive for IL-6R by immunocytochemistry (unlike the remission and normal bone marrow cells above). although two patients (UPN 3 and 4) expressed CD7. All specimens showed a typical t(4;11)(q21;q23) translocation.
Cells from all three IL-6R+ cases showed statistically significant responses to exogenous IL6 in a DNA synthesis assay Patient UPN 1 also had the +8 and isochromosome 7q karyotype. Two other patients (UPN 3 and 5) had an extra chromo- (Table 2 ).
Figure 1
Scatchard plot of data for specific 125 I-IL6 binding to primary leukemic cells from patients with t(4;11)+ ALL. Specific binding of 125 I-IL6 was determined as total inhibitable binding, using a 200-fold excess of unlabelled rIL6 to detect nonspecific binding. Representation of the data in a Scatchard plot gives the number of receptors/cell (x-axis intercept) and dissociation constant (K d ), which is equal to the negativereciprocal slope of the plot; data for calculated receptor density and K d is shown in Table 1 . No specific binding was detected for patients UPN 2, 5 and 6, or for remission and normal bone marrow cells. (Table 1) ; thus, (Figures 2 and 3 ), which were 250-1000-fold lower on a cells expressing higher numbers of receptors tended to be molar basis. more sensitive to IL6-toxin. In contrast, leukemic cells from an IL-6R-negative/t(4;11)+ ALL and bone marrow mononuclear cells from a normal bone marrow specimen (Ͻ20 receptors/cell) were not significantly inhibited by IL6-PE 4E at doses up to 1000 ng/ml. Similarly, proliferation of normal graLeukemic engraftment assay for sensitivity of t(4;11)+ nulocyte-macrophage and erythroid progenitor cells (CFU-ALL cells to IL6-PE 4E GM and BFU-E, respectively) in clonogenic assays was not inhibited by IL6-PE 4E at doses up to 1000 ng/ml, although slight but statistically significant inhibition was noted at Recombinant IL6-PE 4E was able to prevent engraftment of pri-2500 ng/ml (Table 3) . mary ALL cells from patients UPN 3 (2100 IL-6R/cell) and To compare the effects of IL6-toxin and chemotherapeutic UPN 4 (1560 IL-6R/cell). In these experiments, 3-4 × 10 7 cells were incubated with 10 3 ng/ml IL6-PE 4E for 24 h and then inoculated i.v. into SCID mice (5 × 10 6 viable cells/mouse); Table 2 Response of leukemic cells to IL-6 viability was assessed by trypan-blue dye exclusion, and was 54% and 62% for IL6-PE In vitro sensitivity of primary t(4;11)+ ALL cells from UPN 3 (expressing 2100 IL-6R/cell) to IL6-PE 4E , doxorubicin and etoposide as detected by XTT assay. Cells (2 × 10 5 /well) were incubated with different concentrations of the above agents for 48 h prior to reading the assay. cells in all seven AMLL patients studied. Although these cases were primarily adults and the presence of t(4;11) translocation 500 102 ± 9 9 3 ± 8
was not reported, these AMLL cases expressed CD7 and other 1000 98 ± 2 8 4 ± 6 T lineage, B lineage (eg CD19) and myeloid-associated anti- The t(4;11)(q21;p23) translocation is of special interest in Several previous studies have reported expression of IL-6R pediatric acute leukemia because of its relatively frequent mRNA by leukemic cells from adult patients with AML and occurrence and associated poor prognosis. The translocation AMLL; lower levels of IL-6R gene expression by leukemic cells has been linked with expression of biphenotypic features of were detected in approximately 50% of adult ALL cases studearly B cell and myeloid lineages, and a gene designated MLL ied. 10-12 Gene expression was detected by Northern blotting (mixed lineage leukemia) or ALL-1 has been identified at the and quantitative reverse-transcription polymerase chain reac11q23 breakpoint. [25] [26] [27] In this study, we have examined the tion (RT-PCR), although expression of receptor protein itself expression of IL-6R by leukemic cells from six patients with was not examined. Also, AML and AMLL cells (but not ALL t(4;11)+ ALL. Leukemic cells from three patients expressed cells) expressing IL-6R generally showed a proliferative elevated levels of IL-6R relative to bone marrow mononuclear response to exogenous IL-6. 11 In the present study, all three cells from a normal marrow and from a remission marrow cases of IL-6R+ ALL showed statistically significant proliferatobtained from patient UPN 3. Of interest was our finding that ive responses to IL-6, and thus resembled the AMLL cells in all three IL-6R+ cases expressed CD33 along with CD19, the Inoue study. although none of the IL-6R− cases expressed this antigen.
The t(4;11) translocation is associated with particularly poor Additionally, two of the three IL-6R+ cases expressed the T prognosis in pediatric ALL. In one study of 40 cases, less than cell/myeloid antigen CD7, an antigen previously reported on 10% of infants Ͻ1 year and children Ͼ10 years of age were adult acute mixed lineage leukemia (AMLL) cells. 28 Based on expected to be long-term survivors. 3 The high level of IL-6R the co-expression of multiple myeloid-specific and myeloidexpression on primary t(4;11)+ cells compared to normal bone associated antigens, including CD13, 15 and 33, the above IL-6R+ ALL cases have characteristics of the biphenotypic or marrow progenitor cells suggests that receptor-targeted ther- apy might be clinically useful. Siegall et al 13 have developed values for inhibition of protein synthesis ranging from Ͻ1 ng/ml to 140 ng/ml. 16 In the present study, we used a stana chimeric molecule, IL6-PE 4E , which is composed of IL-6 and a derivative of the 66 kDa Pseudomonas exotoxin (PE 4E ). The dard cytotoxicity assay (XTT) to detect sensitivity of t(4;11)+ cells to IL6-PE
4E
. ID 50 values for the three IL-6R+ cases studied latter moiety has been modified to abrogate binding to the PE cell-surface receptor by substitution of four glutamine residues ranged from 23-92 ng/ml (0.28-1.1 nM). Since these primary leukemic cells were obtained from patients who had relapsed for naturally occurring amino acids in the PE cell-binding domain (domain I). IL6-PE 4E is up to eight-fold more toxic for and were refractory to therapy, we compared the sensitivity of cells to IL6-toxin and two chemotherapeutic drugs IL-6R+ tumor cells than is IL6-PE40, in which a truncated, 40 kDa PE lacking domain I is conjugated to IL-6. respectively) in clonogenic assays was not inhibited by IL6- we have obtained similar findings in a study of pediatric AML myeloperoxidase mRNA(+) acute lymphoblastic leukemia cell line patients. 37 We are currently evaluating the sensitivity of
